Robyn Karnauskas

Deutsche Bank released a mid-day report Tuesday on Regeneron Pharmaceuticals (NASDAQ: REGN) in which the firm maintained its Buy rating and raised the price target from $375 to $410. In evaluating Regeneron, Deutsche Bank's Robyn Karnauskas noted the key take away from Regeneron's fourth quarter...

In a report published Monday, Deutsche Bank analyst Robyn Karnauskas reiterated a Buy rating on Alexion Pharmaceuticals (NASDAQ: ALXN), and raised the price target from $125.00 to $205.00. In the report, Deutsche Bank noted, “The next new product launch for Alexion is Asfotase Alfa for severe...

In a report published Friday, Deutsche Bank analyst Robyn Karnauskas reiterated a Buy rating and $340.00 price target on Biogen Idec (NASDAQ: BIIB). In the report, Deutsche Bank noted, “Our calculations on IMS data for Tecfidera for week ending 11/22 indicate strong Tecfidera at $363M-$365M in Q4'...

In a report published Wednesday, Deutsche Bank analyst Robyn Karnauskas reiterated a Buy rating on Amgen (NASDAQ: AMGN), and raised the price target from $138.00 to $142.00. In the report, Deutsche Bank noted, “We attended a biosimilar conference in order to learn more about the OPP'Y for Amgen....

In a report published Wednesday, Deutsche Bank analyst Robyn Karnauskas reiterated a Buy rating on Aegerion Pharmaceuticals (NASDAQ: AEGR), and raised the price target from $107.00 to $115.00. In the report, Deutsche Bank noted, “Following the Aegerion analyst day and our recent channel checks we...

In a report published late Tuesday, Deutsche Bank analyst Robyn Karnauskas downgraded the rating on Sarepta Therapeutics (NASDAQ: SRPT) from Buy to Hold, and lowered the price target from $71.00 to $17.00. In the report, Deutsche Bank noted, “Sarepta announced that the FDA now says NDA filing is...

In a report published Thursday, Deutsche Bank analyst Robyn Karnauskas downgraded the rating on Viropharma (NASDAQ: VPHM) from Buy to Hold, but raised the price target from $38.00 to $43.00. In the report, Deutsche Bank noted, “Press sources on 9/13 (Bloomberg) stated that Viropharma has hired an...

In a report published Thursday, Deutsche Bank analyst Robyn Karnauskas reiterated a Buy rating on Neurocrine Biosciences (NASDAQ: NBIX), and raised the price target from $15.00 to $25.00. In the report, Deutsche Bank noted, “Over the next 12 months we see four key catalysts that will provide...

In a report published Friday, Deutsche Bank analyst Robyn Karnauskas downgraded the rating on Dendreon Corporation (NASDAQ: DNDN) from Hold to Sell, and lowered the price target from $6.00 to $1.00. In the report, Deutsche Bank noted, “We see several headwinds over next 12-18 mos that in our view...

In a report published Monday, Deutsche Bank analyst Robyn Karnauskas downgraded Onyx Pharmaceuticals (NASDAQ: ONXX) from Buy to Hold, but raised the price target from $110.00 to $140.00. In the report, Deutsche Bank noted, “Onyx confirmed on 7/16 that it is actively accepting bids from...

In a report published Wednesday, Deutsche Bank analyst Robyn Karnauskas reiterated a Buy rating and $45.00 price target on Sarepta Therapeutics (NASDAQ: SRPT). In the report, Deutsche Bank noted, “Our base case scenario assumes Breakthrough designation for Eteplirsen. However we note that, if...

In a report published on Monday, Deutsche Bank analyst Robyn Karnauskas upgraded BioMarin Pharmaceuticals (NASDAQ: BMRN) to Buy and maintained a price target of $75.00. In the report, Deutsche Bank noted, "We are upgrading Biomarin from Hold to Buy for two reasons. (1) newsflow on competitor...